Payment overview · 2025
General Payments
$853.54
41 reported records · 15 companies
Healthcare provider profile · identity verified
Cullen Michael Ocmond, MD
Allopathic & Osteopathic Physicians|Family Medicine · LUTCHER, LA · NPI 1053588467
Verified facts
What the public records show
CMS Open Payments records show Cullen Michael Ocmond, MD received $853.54 in general payments during 2025 across 41 reported records.
Amgen Inc. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $238.67 | 28.0% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $108.43 | 12.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.71 | 9.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.42 | 8.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.99 | 8.8% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.03 | 8.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.35 | 3.6% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.60 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.44 | 3.3% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.85 | 2.4% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $19.14 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.60 | 2.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.38 | 2.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.38 | 2.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.55 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $835.54 | 40 |
| Education | $18.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $205.88 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $108.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $100.73 | 11 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $84.71 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.99 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.99 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.03 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 180 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
180 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 588 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 113 |
| Losartan Potassium | Losartan Potassium | 435 | 85 |
| Montelukast Sodium | Montelukast Sodium | 357 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 69 |
| Lisinopril | Lisinopril | 331 | 73 |
| Omeprazole | Omeprazole | 312 | 71 |
| Alprazolam | Alprazolam | 297 | 51 |
| Metformin Hcl | Metformin Hcl | 296 | 69 |
| Gabapentin | Gabapentin | 273 | 61 |
| Diclofenac Sodium | Diclofenac Sodium | 256 | 97 |
| Furosemide | Furosemide | 227 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 47 |
| Celecoxib | Celecoxib | 216 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 50 |
| Methylprednisolone | Methylprednisolone | 192 | 152 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 45 |
| Trazodone Hcl | Trazodone Hcl | 181 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 181 | 33 |
| Jardiance | Empagliflozin | 180 | 34 |
| Glipizide Er | Glipizide | 177 | 38 |
| Simvastatin | Simvastatin | 170 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 35 |
| Tramadol Hcl | Tramadol Hcl | 134 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 20 |
| Ezetimibe | Ezetimibe | 126 | 28 |
| Atenolol | Atenolol | 125 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 50 |
| Januvia | Sitagliptin Phosphate | 109 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 25 |
| Mounjaro | Tirzepatide | 108 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 19 |
| Meloxicam | Meloxicam | 102 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 18 |
| Allopurinol | Allopurinol | 99 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 22 |
| Pregabalin | Pregabalin | 85 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 39 |
| Donepezil Hcl | Donepezil Hcl | 76 | 20 |
| Potassium Chloride | Potassium Chloride | 75 | 19 |
| Eliquis | Apixaban | 73 | 14 |
| Carvedilol | Carvedilol | 71 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 15 |
| Prednisone | Prednisone | 67 | 55 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 14 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Spironolactone | Spironolactone | 61 | 11 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Bupropion Xl | Bupropion Hcl | 49 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 29 |
| Ondansetron Odt | Ondansetron | 45 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 36 |
| Ozempic | Semaglutide | 39 | 13 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Cefdinir | Cefdinir | 35 | 31 |
| Finasteride | Finasteride | 35 | suppressed |
| Nystatin | Nystatin | 35 | 18 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | 11 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 28 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Naproxen | Naproxen | 21 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Mupirocin | Mupirocin | 18 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $853.54 · 41 records | Amgen Inc. | AREXVY, Auvelity, CAPVAXIVE, FANAPT, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, JARDIANCE, JOURNAVX, KRYSTEXXA, LINZESS, LOREEV XR, MOUNJARO, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error